ACAD
Acadia Pharmaceuticals Inc.
September 24, 2026 · market open
- Rarity
- 3.41
- Peak move
- −13.02%
- Float cap
- $4.3B
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on neurological and rare diseases. It markets NUPLAZID (pimavanserin) in the United States for hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide) for Rett syndrome, including in the United States, Canada, and Israel. It also develops product candidates for Alzheimer's disease psychosis, Lewy body dementia psychosis, major depressive disorder, essential tremor, and Huntington's disease.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
3 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowBank of America Corp DE disclosed a new position of 1,300,385 Acadia Pharmaceuticals shares worth about $32.9 million, or a 0.75% stake, in its most recent Form 13F filing for the second quarter.
analyst_ratingOppenheimer reiterated a Market Perform rating on Acadia Pharmaceuticals (ACAD) with a $25.00 price target on September 23, 2026, calling the upcoming Phase 2 RADIANT topline data for remlifanserin in Alzheimer's disease psychosis the key near-term catalyst, expected in September or October.
clinical_readoutAcadia reported Phase 3-enabling topline results from the Phase 2 portion of the RADIANT trial of remlifanserin in Alzheimer's disease psychosis, with the 60 mg dose showing a -12.6 SAPS-H+D change vs -10.4 for placebo at week 6 (p=0.0603), narrowly missing the primary endpoint, and Acadia will continue Phase 3 while removing the 30 mg arm.